Notice of Meeting, 20854 [2010-9035]
Download as PDF
<![CDATA[
20854
Federal Register / Vol. 75, No. 76 / Wednesday, April 21, 2010 / Notices
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Eye Institute
Special Emphasis Panel, Immunosuppression
for Eye Diseases.
Date: April 20, 2010.
Time: 3 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Eye Institute, 5635 Fishers
Lane, 1300, Bethesda, MD 20892.
Contact Person: Samuel Rawlings, PhD,
Chief, Scientific Review Branch, Division of
Extramural Research, National Eye Institute,
5635 Fishers Lane, Suite 1300, MSC 9300,
Bethesda, MD 20892–9300, 301–451–2020,
rawlings@nei.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93867, Vision Research,
National Institutes of Health, HHS)
Dated: April 8, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–8846 Filed 4–20–10; 8:45 am]
BILLING CODE 4140–01–M
Federal Advisory Committee Act,
section 10(d) of 5 U.S.C., Appendix 2
and 5 U.S.C. 552b(c)(6). Grant
applications for the Recovery Act 2009
Limited Competition: AHRQ Clinical
and Health Outcomes Initiative in
Comparative Effectiveness (CHOICE)
Grants (R01) applications are to be
reviewed and discussed at this meeting.
These discussions are likely to reveal
personal information concerning
individuals associated with the
applications. This information is
exempt from mandatory disclosure
under the above-cited statutes.
SEP Meeting on: Recovery Act 2009
Limited Competition: AHRQ Clinical and
Health Outcomes Initiative in Comparative
Effectiveness (CHOICE) Grants (R01).
Date: April 28–30, 2010 (Open on April 28
from 8 a.m. to 8:15 a.m. and closed for the
remainder of the meeting).
Place: Doubletree Bethesda Hotel &
Executive Meeting Center, 8120 Wisconsin
Avenue, Conference Room TBD, Bethesda,
Maryland 20852.
Contact Person: Anyone wishing to obtain
a roster of members, agenda or minutes of the
nonconfidential portions of this meeting
should contact Mrs. Bonnie Campbell,
Committee Management Officer, Office of
Extramural Research, Education and Priority
Populations, AHRQ, 540 Gaither Road, Room
2038, Rockville, Maryland 20850, Telephone
(301) 427–1554.
Agenda items for this meeting are subject
to change as priorities dictate.
This notice is published less than 15 days
in advance of the meeting date due to
logistical difficulties.
Dated: April 13, 2010.
Carol M. Clancy,
Director.
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Agency for Healthcare Research and
Quality
[FR Doc. 2010–9035 Filed 4–20–10; 8:45 am]
BILLING CODE 4160–90–M
erowe on DSK5CLS3C1PROD with NOTICES
Notice of Meeting
In accordance with section 10(d) of
the Federal Advisory Committee Act (5
U.S.C., Appendix 2), announcement is
made of a Health Care Policy and
Research Special Emphasis Panel (SEP)
meeting.
A Special Emphasis Panel is a group
of experts in fields related to health care
research who are invited by the Agency
for Healthcare Research and Quality
(AHRQ), and agree to be available, to
conduct on an as needed basis,
scientific reviews of applications for
AHRQ support. Individual members of
the Panel do not attend regularlyscheduled meetings and do not serve for
fixed terms or a long period of time.
Rather, they are asked to participate in
particular review meetings which
require their type of expertise.
Substantial segments of the upcoming
SEP meeting listed below will be closed
to the public in accordance with the
VerDate Nov<24>2008
14:33 Apr 20, 2010
Jkt 220001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2010–N–0202]
Medical Device Use in the Home
Environment: Implications for the Safe
and Effective Use of Medical Device
Technology Migrating Into the Home;
Public Workshop; Request for
Comments
AGENCY:
Food and Drug Administration,
HHS.
ACTION: Notice of public workshop;
request for comments.
The Food and Drug Administration
(FDA) is announcing a public workshop
entitled Medical Device Use in the
Home Environment: Implications for the
Safe and Effective Use of Medical
Device Technology Migrating Into the
PO 00000
Frm 00049
Fmt 4703
Sfmt 4703
Home. The purpose of the workshop is
to solicit information from healthcare
providers, academics, human factors
experts, medical device manufacturers
and distributors, professional societies,
patient advocacy groups, patients, and
caregivers, on the challenges
surrounding medical device technology
in the home environment. FDA seeks
input and comments on a number of
identified topics related to medical
device home use.
Dates and Times: The public
workshop will be held on May 24, 2010,
from 7:30 a.m. to 5 p.m. Persons
interested in attending and/or
participating in the workshop must
register by 5 p.m. on May 17, 2010.
Submit written or electronic comments
by June 30, 2010.
Location: The public workshop will
be held at the Hilton Hotel, 8727
Colesville Rd., Silver Spring, MD 20910.
The hotel’s front desk telephone number
is 301–589–5200.
Contact Person: Mary Brady, Center
for Devices and Radiological Health,
Food and Drug Administration, 10903
New Hampshire Ave., Bldg. 66, rm.
2320, Silver Spring, MD 20993–0002, email: Mary.Brady@fda.hhs.gov
(preferable), 301–796–6089.
Registration and Requests for Oral
Comments: If you wish to attend the
public meeting, you must register online
at https://www.fda.gov/MedicalDevices/
NewsEvents/WorkshopsConferences/
default.htm (select the appropriate
meeting from the list). Please provide
complete contact information for each
attendee, including name, title,
organization or company, address, email, and telephone number.
Registrations must be submitted by May
17, 2010.
If you wish to make an oral comment
during general sessions of the public
workshop (see section III of this
document), you must indicate this in
your registration. Please also identify
which topics you wish to address in
your oral comment. Topics for
discussion are listed in section II of this
document. FDA will do its best to
accommodate all persons who wish to
make oral comments during the general
sessions. However, FDA strongly
recommends that you provide written or
electronic comments as instructed in
this document to ensure that your
comments are captured. Please refer to
the section entitled Comments for
instructions on submitting written or
electronic comments.
Registration is free and will be on a
first-come, first-served basis. Early
registration is encouraged because
seating is limited. There will be no
onsite registration.
E:\FR\FM\21APN1.SGM
21APN1
]]>Agencies
[Federal Register Volume 75, Number 76 (Wednesday, April 21, 2010)]
[Notices]
[Page 20854]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-9035]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Agency for Healthcare Research and Quality
Notice of Meeting
In accordance with section 10(d) of the Federal Advisory Committee
Act (5 U.S.C., Appendix 2), announcement is made of a Health Care
Policy and Research Special Emphasis Panel (SEP) meeting.
A Special Emphasis Panel is a group of experts in fields related to
health care research who are invited by the Agency for Healthcare
Research and Quality (AHRQ), and agree to be available, to conduct on
an as needed basis, scientific reviews of applications for AHRQ
support. Individual members of the Panel do not attend regularly-
scheduled meetings and do not serve for fixed terms or a long period of
time. Rather, they are asked to participate in particular review
meetings which require their type of expertise.
Substantial segments of the upcoming SEP meeting listed below will
be closed to the public in accordance with the Federal Advisory
Committee Act, section 10(d) of 5 U.S.C., Appendix 2 and 5 U.S.C.
552b(c)(6). Grant applications for the Recovery Act 2009 Limited
Competition: AHRQ Clinical and Health Outcomes Initiative in
Comparative Effectiveness (CHOICE) Grants (R01) applications are to be
reviewed and discussed at this meeting. These discussions are likely to
reveal personal information concerning individuals associated with the
applications. This information is exempt from mandatory disclosure
under the above-cited statutes.
SEP Meeting on: Recovery Act 2009 Limited Competition: AHRQ
Clinical and Health Outcomes Initiative in Comparative Effectiveness
(CHOICE) Grants (R01).
Date: April 28-30, 2010 (Open on April 28 from 8 a.m. to 8:15
a.m. and closed for the remainder of the meeting).
Place: Doubletree Bethesda Hotel & Executive Meeting Center,
8120 Wisconsin Avenue, Conference Room TBD, Bethesda, Maryland
20852.
Contact Person: Anyone wishing to obtain a roster of members,
agenda or minutes of the nonconfidential portions of this meeting
should contact Mrs. Bonnie Campbell, Committee Management Officer,
Office of Extramural Research, Education and Priority Populations,
AHRQ, 540 Gaither Road, Room 2038, Rockville, Maryland 20850,
Telephone (301) 427-1554.
Agenda items for this meeting are subject to change as
priorities dictate.
This notice is published less than 15 days in advance of the
meeting date due to logistical difficulties.
Dated: April 13, 2010.
Carol M. Clancy,
Director.
[FR Doc. 2010-9035 Filed 4-20-10; 8:45 am]
BILLING CODE 4160-90-M
